Bannerbild German Brest Group

Paper of the month: models for pCR

27.09.2018

A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.

Contemp Clin Trials

The pCR rate can be assessed at the time of surgery in the neoadjuvant setting. Therefore, the US Food and Drug Administration (FDA) funded a meta-analysis of 12 international neoadjuvant trials in patients with early breast cancer (CTNeoBC; Cartazar et al. Lancet 2014) to evaluate pCR rate as a potential surrogate endpoint for prediction of long-term clinical benefit in breast cancer. The trial-level data from this analysis was used as a training data set to develop the statistical predictive model presented in the current study. The data from three other studies including GeparSixto was used to validate the new predictor. The model is able to predict the correlation between pCR and event-free survival as well as overall survival in patients with high risk early breast cancer.

Nekljudova V, Loibl S, von Minckwitz G, Schneeweiss A, Glück S, Crane R, Li H, Luo X.
Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC).
Contemp Clin Trials. 2018 71:194-198

Link in PubMed

News

  • 29.11.2018 GBG Research at SABCS

    Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.

    Mehr ...
  • 15.11.2018 Save the Date: AGO-Mamma 2019

    Save the Date: AGO-Mamma 2019

    Das State-of-the-Art-Meeting 2019 der AGO Organkomission Mamma wird am 16. März 2019 in Frankfurt stattfinden.

    Mehr ...
  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

    Mehr ...
  • 15.10.2018 GBG Research at ESMO

    Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd